The FDA approved lunsotogene parvec-cwha as the first gene therapy for genetic hearing loss caused by biallelic OTOF variants. The US Food and Drug Administration (FDA) has approved lunsotogene parvec ...
Antibiotics dominate early care: More than half of pediatric patients received combination systemic antibiotics and topical therapies as first-line treatment, while biologic use remained low.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results